Guangdong Lifestrong Pharmacy Past Earnings Performance
Past criteria checks 1/6
Guangdong Lifestrong Pharmacy's earnings have been declining at an average annual rate of -26%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 3.7% per year. Guangdong Lifestrong Pharmacy's return on equity is 2.1%, and it has net margins of 5.4%.
Key information
-26.0%
Earnings growth rate
-34.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -3.7% |
| Return on equity | 2.1% |
| Net Margin | 5.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Guangdong Lifestrong Pharmacy's (SZSE:301111) Anemic Earnings Might Be Worse Than You Think
Nov 04
Guangdong Lifestrong Pharmacy's (SZSE:301111) Problems Go Beyond Weak Profit
May 03Recent updates
Guangdong Lifestrong Pharmacy's (SZSE:301111) Anemic Earnings Might Be Worse Than You Think
Nov 04Investor Optimism Abounds Guangdong Lifestrong Pharmacy Co., Ltd. (SZSE:301111) But Growth Is Lacking
Oct 02Guangdong Lifestrong Pharmacy's (SZSE:301111) Problems Go Beyond Weak Profit
May 03What Guangdong Lifestrong Pharmacy Co., Ltd.'s (SZSE:301111) 28% Share Price Gain Is Not Telling You
Mar 06Revenue & Expenses Breakdown
How Guangdong Lifestrong Pharmacy makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 315 | 17 | 181 | 9 |
| 30 Jun 24 | 298 | 24 | 173 | 9 |
| 31 Mar 24 | 284 | 30 | 164 | 9 |
| 31 Dec 23 | 292 | 34 | 166 | 8 |
| 30 Sep 23 | 283 | 33 | 156 | 8 |
| 30 Jun 23 | 296 | 33 | 160 | 8 |
| 31 Mar 23 | 302 | 35 | 162 | 9 |
| 01 Jan 23 | 283 | 33 | 156 | 9 |
| 30 Sep 22 | 297 | 45 | 155 | 10 |
| 30 Jun 22 | 317 | 52 | 154 | 11 |
| 31 Mar 22 | 347 | 60 | 167 | 11 |
| 01 Jan 22 | 350 | 57 | 166 | 11 |
| 01 Oct 21 | 350 | 61 | 161 | 11 |
| 31 Dec 20 | 341 | 63 | 147 | 11 |
| 31 Dec 19 | 317 | 67 | 143 | 8 |
| 31 Dec 18 | 290 | 64 | 116 | 7 |
| 31 Dec 17 | 192 | 33 | 55 | 7 |
Quality Earnings: 301111 has high quality earnings.
Growing Profit Margin: 301111's current net profit margins (5.4%) are lower than last year (11.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301111's earnings have declined by 26% per year over the past 5 years.
Accelerating Growth: 301111's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 301111 had negative earnings growth (-47.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).
Return on Equity
High ROE: 301111's Return on Equity (2.1%) is considered low.